Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

DHODH is an independent prognostic marker and potent therapeutic target in neuroblastoma
Thale Kristin Olsen, Cecilia Dyberg, Bethel Tesfai Embaie, et al.
JCI Insight (2022) Vol. 7, Iss. 17
Open Access | Times Cited: 23

Showing 23 citing articles:

Ferroptosis: a new hunter of hepatocellular carcinoma
Yulang Jiang, Yongxin Yu, Ziyang Pan, et al.
Cell Death Discovery (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 20
Emerging roles of nucleotide metabolism in cancer
Diana D. Shi, Milan R. Savani, Kalil G. Abdullah, et al.
Trends in cancer (2023) Vol. 9, Iss. 8, pp. 624-635
Open Access | Times Cited: 32
Small-molecule agents for cancer immunotherapy
Fang Wang, Kai Fu, Yujue Wang, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 14, Iss. 3, pp. 905-952
Open Access | Times Cited: 23
Study of an N6-methyladenosine- and ferroptosis-related prognostic model and the mechanisms underlying the molecular network in neuroblastoma based on multiple datasets
Jing Chu
Discover Oncology (2025) Vol. 16, Iss. 1
Open Access
Targeting vulnerability in tumor therapy: Dihydroorotate dehydrogenase
Fu Lin, Jiaxin Li, Lei Zhou, et al.
Life Sciences (2025), pp. 123612-123612
Closed Access
Ginsenoside RK1 Induces Ferroptosis in Hepatocellular Carcinoma Cells through an FSP1-Dependent Pathway
Yulang Jiang, Yongxin Yu, Ziyang Pan, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 7, pp. 871-871
Open Access | Times Cited: 3
ENT1 blockade by CNX-774 overcomes resistance to DHODH inhibition in pancreatic cancer
Nicholas J. Mullen, Ravi Thakur, Surendra K. Shukla, et al.
Cancer Letters (2022) Vol. 552, pp. 215981-215981
Open Access | Times Cited: 15
Defining neuroblastoma: from origin to precision medicine
Lourdes Sainero‐Alcolado, Tomas Sjöberg Bexelius, Giuseppe Santopolo, et al.
Neuro-Oncology (2024) Vol. 26, Iss. 12, pp. 2174-2192
Open Access | Times Cited: 2
Metabolic reprogramming of cancer cells by JMJD6-mediated pre-mRNA splicing associated with therapeutic response to splicing inhibitor
Carolyn M. Jablonowski, Waise Quarni, Shivendra V. Singh, et al.
eLife (2023) Vol. 12
Open Access | Times Cited: 6
DHODH: a promising target in the treatment of T-cell acute lymphoblastic leukemia
Amy Sexauer, Gabriela Alexe, Karin Gustafsson, et al.
Blood Advances (2023) Vol. 7, Iss. 21, pp. 6685-6701
Open Access | Times Cited: 5
Bioinformatics analysis and experimental verification of the cancer-promoting effect of DHODH in clear cell renal cell carcinoma
Songsong Wang, Yan Li, Yilong Lin, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 1
Radiosynthesis of [18F]Brequinar for in vivo PET Imaging of hDHODH for Potential Studies of Acute Myeloid Leukemia and Cancers
Vinay Kumar Banka, Stefano Sainas, Elena Martino, et al.
RSC Medicinal Chemistry (2024) Vol. 15, Iss. 9, pp. 3147-3161
Open Access | Times Cited: 1
Metabolic targeting of neuroblastoma, an update.
Leila Jahangiri
Cancer Letters (2024), pp. 217393-217393
Open Access | Times Cited: 1
Proof-of-principle studies on a strategy to enhance nucleotide imbalance specifically in cancer cells
Twana Alkasalias, Juan Zhang, Harsha S. Madapura, et al.
Cell Death Discovery (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 3
Reviewer #1 (Public Review): Metabolic reprogramming of cancer cells by JMJD6-mediated pre-mRNA splicing is associated with therapeutic response to splicing inhibitor

(2024)
Open Access
Metabolic reprogramming of cancer cells by JMJD6-mediated pre-mRNA splicing is associated with therapeutic response to splicing inhibitor
Carolyn M. Jablonowski, Waise Quarni, Shivendra V. Singh, et al.
(2024)
Open Access
Author Response: Metabolic reprogramming of cancer cells by JMJD6-mediated pre-mRNA splicing is associated with therapeutic response to splicing inhibitor
Carolyn M. Jablonowski, Waise Quarni, Shivendra V. Singh, et al.
(2024)
Open Access
Metabolic reprogramming of cancer cells by JMJD6-mediated pre-mRNA splicing associated with therapeutic response to splicing inhibitor
Carolyn M. Jablonowski, Waise Quarni, Shivendra V. Singh, et al.
eLife (2024) Vol. 12
Open Access
DHODH Inhibition Suppresses MYC and Inhibits the Growth of Medulloblastoma in a Novel In Vivo Zebrafish Model
Ioanna Tsea, Thale Kristin Olsen, Panagiotis Alkinoos Polychronopoulos, et al.
Cancers (2024) Vol. 16, Iss. 24, pp. 4162-4162
Open Access
CRISPR-Cas System Is an Effective Tool for Identifying Drug Combinations That Provide Synergistic Therapeutic Potential in Cancers
Yuna Kim, Hyeong-Min Lee
Cells (2023) Vol. 12, Iss. 22, pp. 2593-2593
Open Access | Times Cited: 1
Retinoblastoma vulnerability to combined de novo and salvage pyrimidine ribonucleotide synthesis pharmacologic blockage
Tanzina Mollick, Suhas Darekar, Basile Dalarun, et al.
Heliyon (2023) Vol. 10, Iss. 1, pp. e23831-e23831
Open Access | Times Cited: 1
Tumor Volume of Onset and MYCN Amplification Predict Poor Prognosis in Patients with Neuroblastoma
Fengming Ji, Jianjun Zhu, Chenghao Zhanghuang, et al.
Research Square (Research Square) (2023)
Open Access
Metabolic reprogramming of cancer cells by JMJD6-mediated pre-mRNA splicing is associated with therapeutic response to splicing inhibitor
Carolyn M. Jablonowski, Waise Quarni, Shivendra V. Singh, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
Page 1

Scroll to top